Mentax — Competitive Intelligence Brief

Mentax (BUTENAFINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzylamine Antifungal. Area: Infectious Disease.

marketed Benzylamine Antifungal Cytochrome P450 2D6 Infectious Disease Small molecule

Target snapshot

Mentax (BUTENAFINE) — Bayer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mentax TARGET	BUTENAFINE	Bayer	marketed	Benzylamine Antifungal	Cytochrome P450 2D6	1996-01-01
Chirocain	LEVOBUPIVACAINE	Purdue Pharma Lp	marketed	levobupivacaine	Cytochrome P450 2D6	1999-01-01
PERHEXILINE	PERHEXILINE		marketed	perhexiline	Carnitine O-palmitoyltransferase 1, liver isoform, Carnitine O-palmitoyltransferase 2, mitochondrial, Cytochrome P450 2D6	1974-01-01
Bupivacaine Hydrochloride And Epinephrine	Bupivacaine Hydrochloride	Pfizer	marketed	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	BUPIVACAINE	Innocoll	marketed	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
DIPHENIDOL HYDROCHLORIDE	DIPHENIDOL HYDROCHLORIDE		marketed	Anticholinergic	5-hydroxytryptamine receptor 2A, Cytochrome P450 2D6, D(2) dopamine receptor	1967-01-01
Dopram	DOXAPRAM	Hikma	marketed	Respiratory Stimulant	Cytochrome P450 2D6	1965-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzylamine Antifungal class)

1. Bayer · 1 drug in this class